{"DataElement":{"publicId":"5526315","version":"1","preferredName":"Lymphoproliferative Disease PostBMT Response Category","preferredDefinition":"Identification of the status of lymphoproliferative disease post bone marrow transplantation.","longName":"LYMPH_DZ_POST_DZ_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5525885","version":"1","preferredName":"Lymphoproliferative Disease Timepoint Post Transplantation Disease Response","preferredDefinition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis)._A specific point in the time continuum, including those established relative to an event._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Happening at a time subsequent to a reference time; later in time or order._Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","longName":"5525856v1.0:5525883v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"5525856","version":"1","preferredName":"Lymphoproliferative Disorder","preferredDefinition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","longName":"C9308","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F271308-C686-1558-E053-F662850A6CDA","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5525883","version":"1","preferredName":"Timepoint Post Transplantation Disease Response","preferredDefinition":"A specific point in the time continuum, including those established relative to an event.:Happening at a time subsequent to a reference time; later in time or order.:Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C68568:C38008:C15342:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2AFC-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2B0D-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunosuppression CRF template.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5525886","version":"1","preferredName":"Lymphoproliferative Disorder PostBMT Response Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"LYMPH_BMT_RESP_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete remission without additional therapy","valueDescription":"Complete Remission Without Additional Therapy Required ","ValueMeaning":{"publicId":"5525889","version":"1","preferredName":"Complete Remission Without Additional Therapy Required ","longName":"5525889","preferredDefinition":"The non-affirmative response to a question.: Added; extra; further.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2B8A-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2BA3-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"},{"value":"Partial remission without additional therapy","valueDescription":"Partial Remission Without Additional Therapy Required ","ValueMeaning":{"publicId":"5525887","version":"1","preferredName":"Partial Remission Without Additional Therapy Required ","longName":"5525887","preferredDefinition":"The non-affirmative response to a question.: Added; extra; further.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2B39-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2B52-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"},{"value":"Partial remission with additional therapy","valueDescription":"Partial Remission With Additional Therapy Required ","ValueMeaning":{"publicId":"5525888","version":"1","preferredName":"Partial Remission With Additional Therapy Required ","longName":"5525888","preferredDefinition":"Added; extra; further.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2B61-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2B7A-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"},{"value":"Complete remission with additional therapy","valueDescription":"Complete Remission No Additional Therapy Required ","ValueMeaning":{"publicId":"5525890","version":"1","preferredName":"Complete Remission No Additional Therapy Required ","longName":"5525890","preferredDefinition":"Added; extra; further.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F27A5BA-2BB2-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2BCB-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"},{"value":"Active disease not requiring therapy","valueDescription":"Lymphoproliferative Disease No Additional Therapy Required","ValueMeaning":{"publicId":"5525879","version":"1","preferredName":"Lymphoproliferative Disease No Additional Therapy Required","longName":"5525879","preferredDefinition":"The non-affirmative response to a question.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F2780C2-F876-5C18-E053-F662850AFFA1","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2BD5-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"},{"value":"Active disease requiring therapy","valueDescription":" Lymphoproliferative Disease Additional Therapy Required ","ValueMeaning":{"publicId":"5525880","version":"1","preferredName":" Lymphoproliferative Disease Additional Therapy Required ","longName":"5525880","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.: Something that is a necessary condition; something that is obligatory.: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3F2780C2-F89D-5C18-E053-F662850AFFA1","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3F27A5BA-2BE0-6999-E053-F662850A8C54","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"ONEDATA","dateModified":"2016-10-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3F27A5BA-2B20-6999-E053-F662850A8C54","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunodeficiency CRF Template.  Value sets are prescribed for that specific set of requirements.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Post-BMT lymphoproliferative","type":"Preferred Question Text","description":"Post-BMT lymphoproliferative disease status","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3F2780C2-F8FA-5C18-E053-F662850AFFA1","latestVersionIndicator":"Yes","beginDate":"2016-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-18","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunosuppression CFR Template.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}